YOLFTbeta
QuantaMatrix Inc.

QuantaMatrix Inc.

317690 · KQ · Healthcare / Medical Devices

1,721.00KRW-49.00 (-2.77%)

Price History

Full chart

Market Stats

Previous Close1,770.00
Open1,789.00
Day Range1,705.00 – 1,789.00
52-Week Range1,927.00 – 5,660.00
Volume32.37K
Market Cap46.41B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta0.26
50-Day Avg2,341.56
200-Day Avg3,346.82

About

QuantaMatrix Inc. operates as an in-vitro diagnostics company in South Korea. Its products include dRAST, a direct and rapid antimicrobial susceptibility test for treating sepsis that provides MIC-based phenotypic antimicrobial susceptibility testing direct from positive blood culture; QDST, a rapid phenotypic drug susceptibility testing system for tuberculosis; QPLEX Alz plus assay, an early diagnosis kit for Alzheimer's disease; and Quanti9 and QuantiGal, a prognostic prediction kit for cardiovascular diseases. QuantaMatrix Inc. was founded in 2010 and is based in Seoul, South Korea.

Company Details

  • SectorHealthcare
  • IndustryMedical Devices
  • CEODr. Sung Hoon Kwon
  • Employees90
  • HeadquartersBldg.B, BYC HIGHCITY, 131, Seoul, South Korea, 08506, Korea
  • Websitehttps://www.quantamatrix.com

Leadership

  • Dr. Sung Hoon KwonPresident & CEO

Financials

Income Statement

Currency: KRW2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue46.53M84.94M811.38M1.69B549.77M1.29B3.12B2.50B3.69B
Growth (%)-+82.55%+855.21%+108.20%-67.46%+133.90%+142.47%-19.91%+47.70%
Cost of Revenue26.25M0452.52M1.22B317.90M723.60M2.13B1.59B2.08B
Gross Profit20.28M84.94M358.87M471.87M231.87M562.33M988.55M909.49M1.61B
Gross Margin43.58%100.00%44.23%27.93%42.18%43.73%31.71%36.42%43.72%
Operating Expense8.38B11.18B14.94B15.30B18.71B20.58B23.44B17.05B17.18B
Operating Income-8.36B-11.09B-14.58B-14.83B-18.48B-20.02B-22.45B-16.14B-15.56B
Operating Margin-17971.81%-13056.01%-1797.52%-877.99%-3361.69%-1556.68%-719.95%-646.31%-421.98%
EBITDA------16.76B-19.12B-16.51B-15.63B
EBITDA Margin------1303.62%-613.14%-661.16%-423.87%
Net Income-12.42B-15.51B-63.81B-14.66B-18.12B-19.24B-21.56B-20.17B-19.46B
Net Income Margin-26699.35%-18261.83%-7864.48%-867.72%-3295.13%-1495.97%-691.35%-807.67%-527.63%
R&D--5.74B4.78B5.12B5.49B5.78B4.79B4.31B
R&D as % of Total Revenue--706.88%282.73%931.62%427.10%185.31%191.81%116.87%
Interest Expense000218.55M215.43M166.36M117.74M1.33B1.65B
Interest Expense % of Total Revenue0.00%0.00%0.00%12.94%39.19%12.94%3.78%53.39%44.63%

Balance Sheet

Currency: KRW2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets13.74B31.73B33.19B61.55B63.77B45.60B22.67B26.83B52.67B
Total Liabilities40.41B71.96B3.91B4.15B5.38B5.72B4.55B20.30B12.67B
Total Equity-26.67B-40.23B29.28B57.40B58.39B39.88B18.12B6.53B40.01B
Cash83.26M2.06B2.90B9.49B9.01B2.03B6.86B6.11B38.54B
Total Debt15.41B31.66B1.38B1.26B-----
Net Debt-------9.31B-

Cash Flow

Currency: KRW2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-5.04B-8.09B-14.45B-13.21B-15.00B-16.59B-20.66B-12.93B-15.07B
Investing Cash Flow-10.41B-16.55B1.22B-22.17B-3.53B10.55B26.30B-4.50B-
Financing Cash Flow15.49B26.62B14.07B42.05B18.01B-910.15M-793.75M16.48B-
Capital Expenditure1.91B1.11B1.14B1.11B3.73B1.43B1.83B527.99M677.41M
Free Cash Flow----14.37B-18.73B-18.02B-22.49B-13.46B-15.75B
FCF to OCF---108.80%124.87%108.61%108.87%104.08%104.49%

Earnings

Report DateDec 31, 2020Mar 31, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate-----------------------
EPS Actual-272.07-303.00-278.00-274.00-353.23-324.00-288.04-271.91-282.94-342.62-296.71-318.14-347.71-260.69-158.49-239.80-560.43-241.50-327.53-207.33-270.51-231.65-189.12
Surprise-----------------------
Timing-----------------------

Key Statistics & Ratios

Market Cap46.41B
Enterprise Value19.86B
Trailing P/E0.00
Forward P/E0.00
Price / Sales14.76
Price / Book1.37
Revenue (TTM)3.15B
Gross Profit (TTM)938.25M
EBITDA-14.39B
Profit Margin0.00%
Operating Margin-652.74%
Return on Equity-96.89%
Return on Assets-30.27%
Shares Outstanding20.14M
Shares Float17.44M
Beta0.26
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%